MWMichael Wernecke

Michael Wernecke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Wernecke has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • David J. Graham

    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD (D.J.G.).

    5 shared publications
  • Jeffrey A. Kelman

    Centers for Medicare & Medicaid Services Washington DC USA

    5 shared publications
  • Yoganand Chillarige

    Acumen, LLC, 500 Airport Blvd. Suite 100, Burlingame, CA 94010, United States

    5 shared publications
  • Richard A. Forshee

    Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States

    4 shared publications
  • Azadeh Shoaibi

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America

    3 shared publications
  • Dóra Illei

    Affiliation RTI International, Washington, District of Columbia, United States of America

    3 shared publications

Latest Publications

  • Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World Data

    by Silvia Perez‐Vilar, Wei Hua, Andrew Kwist, Yuxin Ma, Diane Dong, Rongping Zhang, Yong Ma, Andrea Chavez, Nina Huang, Virginia Sheikh, et al.

    Background: The US Food and Drug Administration proposed a five‐level disease severity categorization for baseline COVID‐19 (asymptomatic, mild, moderate, severe, critical). Aims: We conducted a pilot study aimed to validate the performance of the ICD‐10‐CM diagnosis code for COVID‐19 (U07.1) and operational definitions (code‐based algorithms) for each disease severity category in Medicare administrative data. Materials & Methods: We sampled 250 community‐dwelling beneficiaries aged ≥ 18 years with a U07.1 code on an inpatient hospital or ambulatory claim between April 1, 2020 and June 18, 2022. We used stratified sampling based on care setting and COVID‐19 treatment status and adjusted results using sampling weights. Using medical records as the reference standard, we calculated positive predictive values (PPV) and 95% confidence intervals (CI). We conducted prespecified secondary analyses to improve algorithm performance by using refined disease definitions. Results: We received medical records for 190 (77%) beneficiaries. Of these, 171 had a positive SARS‐CoV‐2 test result. The PPV of the COVID‐19 diagnosis code was 89% (CI: 83%–93%) overall, 88% (CI: 80%–93%) in the ambulatory setting, and 93% (CI: 82%–97%) in the inpatient setting. The operational definition for disease severity varied in performance by severity level and measurement strategy. The best performance was: PPV for asymptomatic and mild combined 69% (CI: 59%–77%), PPV for moderate 58% (CI: 34%–78%); PPV for severe 42% (CI: 27%–59%); and PPV for critical 85% (CI: 57%–96%). Discussion: The code, U07.1, reliably identified beneficiaries with COVID‐19 in both ambulatory and inpatient settings. The operational definition to classify COVID‐19 disease severity notably improved performance when we implemented selected refinements. Conclusion: Researchers should consider the moderate performance of the proposed operational definitions when using administrative claims data to assess COVID‐19 disease severity.


  • Open Access

    Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States

    by J. Bradley Layton, Patricia C. Lloyd, Lauren S. Peetluk, Yixin Jiao, Djeneba Audrey Djibo, Joann F. Gruber, Jie Deng, Christine Bui, An-Chi Lo, Rachel P. Ogilvie, et al.

    With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID-19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID-19 vaccines—BNT162b2, mRNA-1273, and JNJ-7836735—in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID-19 and hospital/emergency department (ED)-diagnosed COVID-19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. The study period began 11 December 2020 (date of first COVID-19 vaccine availability in the US) and ended 15 January 2022 in Optum and 31 March 2022 in CVS Health. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID-19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID-19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically diagnosed and up to 9 months for hospital/ED-diagnosed COVID-19. VE differed by brand and variant era. Ongoing real-world surveillance of COVID-19 vaccines using robust data sources and methodology is needed as new variants and recommendations for updated vaccines have evolved.


  • Open Access

    Lessons Learned From Characterizing Long COVID Among US Medicare Beneficiaries

    by Yun Lu, Arnstein Lindaas, Hector S. Izurieta, Myrna Cozen, Mikhail Menis, Xiangyu Shi, Whitney R. Steele, Michael Wernecke, Yoganand Chillarige, Jeffrey A. Kelman, et al.

    Purpose: To characterize long‐term effects of COVID‐19 among older adults (aged ≥ 65 years).Methods: This retrospective descriptive study utilized Medicare Fee‐for‐Service beneficiaries' claims to characterize post‐COVID condition diagnosis code usage, long COVID (defined as post‐COVID condition diagnoses made ≥ 28 days after an initial COVID‐19 diagnosis) incidence, patient demographics, and concurrent diagnoses.Results: During April 1, 2020 to May 21, 2022, 193 691 (0.6%) of 31 847 927 Medicare beneficiaries were diagnosed with post‐COVID conditions using ICD‐10‐CM diagnosis codes U09.9 and B94.8, regardless of prior COVID‐19 diagnosis. Post‐COVID condition diagnosis rate was higher among nursing home residents (18.7 per 1000 person‐years) than community‐dwelling beneficiaries (2.8). Among community‐dwelling beneficiaries with a post‐COVID condition diagnosis, 17.5% did not have any prior COVID‐19 diagnosis code U07.1 recorded. Among beneficiaries with COVID‐19 diagnosis, there were no significant sex, age, or race/ethnicity differences between those with post‐COVID conditions ≥ 28 days after COVID‐19 (i.e., long COVID) and those without post‐COVID conditions. Certain myopathies and interstitial pulmonary disease codes were disproportionately present concurrently with long COVID compared to COVID‐19.Conclusions: In this large study of 32 million Medicare beneficiaries, we found approximately 194 000 post‐COVID condition diagnoses. Post‐COVID condition diagnosis rate was higher among nursing home residents, highlighting the substantial burden of COVID‐19 in this vulnerable population. Community‐dwelling beneficiaries were less likely to seek medical care for COVID‐19 events than nursing home residents, which may suggest differences in COVID‐19 severity and respiratory disease detection between these populations. Long COVID risk after COVID‐19 infection may be similar across demographic groups.


  • The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease

    by Steven T. Bird, Kate Gelperin, Elizabeth R. Smith, Tae Hyun Jung, Hai Lyu, Aliza Thompson, Olivia Easley, Kushal B. Naik, Yueqin Zhao, Rekha Kambhampati, et al.

    There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD). To assess the risk for emergently treated hypocalcemia with denosumab by stage of CKD and presence of CKD-mineral and bone disorder (CKD-MBD). Target trial emulation. Medicare fee-for-service data with prescription drug coverage, 2012 to 2020. Female patients aged 65 years or older initiating denosumab, oral bisphosphonates, or intravenous (IV) bisphosphonates for osteoporosis. Hospital and emergency department admissions (that is, emergent care) for hypocalcemia were assessed in the first 12 treatment weeks. Inverse probability of treatment weighted cumulative incidence and weighted risk differences (RDs) were calculated. A total of 361 453 patients treated with denosumab, 829 044 treated with oral bisphosphonates, and 160 413 treated with IV bisphosphonates were identified. Risk for emergently treated hypocalcemia with denosumab versus oral bisphosphonates increased with worsening CKD stage (P < 0.001), with greatest risk among dialysis-dependent (DD) patients (3.01% vs. 0.00%; RD, 3.01% [95% CI, 2.27% to 3.77%]) and non-dialysis-dependent (NDD) patients with CKD stages 4 and 5 (0.57% vs. 0.03%; RD, 0.54% [CI, 0.41% to 0.68%]). Among patients with stages 4 and 5 CKD (NDD + DD), denosumab had a greater risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD-MBD (1.53% vs. 0.02%; RD, 1.51% [CI, 1.21% to 1.78%]) than in those without CKD-MBD (0.22% vs. 0.03%; RD, 0.19% [CI, 0.08% to 0.31%]). Denosumab also showed increased risk compared with IV bisphosphonates. Generalizability to men and non-Medicare populations. Risk for emergently treated hypocalcemia with denosumab increased with worsening CKD stage and was highest in DD patients and those with CKD-MBD. U.S. Food and Drug Administration.


  • Trends in Medical Encounters Involving Cannabis-Related Disorders Among US Medicare Beneficiaries, 2017–2022

    by Silvia Perez-Vilar, Sara Kazemian, Christina Greene, Pablo Freyria Duenas, Rose Radin, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, Yoganand Chillarige, Jeffrey A. Kelman, et al.

    Objectives. To characterize cannabis-related disorder medical encounter trends in the US Medicare population during 2017 to 2022. Methods. We conducted a descriptive study, which included 56 624 432 beneficiaries aged 65 years or older and 10 247 953 aged 18 to 64 years with disability. All were continuously enrolled in Medicare (Fee-for-Service or Advantage) for 183 or more days before the first day of the calendar year. We identified cannabis-related disorder encounters using International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes and computed annual encounter rates per 10 000 beneficiaries. We used the Mann–Kendall test to analyze trends over time. Results. Annual cannabis-related disorder encounter trends among beneficiaries aged 65 years or older ranged from 15.9 (95% confidence interval [CI] = 15.8, 16.0) to 39.3 (95% CI = 39.1, 39.5) per 10 000. Rates among beneficiaries aged 18 to 64 years with disability ranged from 274.8 (95% CI = 273.6, 276.0) to 373.7 (95% CI = 372.3, 375.2) per 10 000. Rates increased over time across both groups, with average annual increases of 4.3 (95% CI = 3.3, 5.3; P = .01) and 17.1 (95% CI = 11.0, 23.2; P = .02) per 10 000, respectively. Conclusions. Further work is needed to explore the impact of coexisting medical conditions on outcomes that result from cannabis-related disorders. ( Am J Public Health. 2024;114(S8):S694–S697. https://doi.org/10.2105/AJPH.2024.307729 )


  • Open Access

    Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older During the BA.1/BA.2 Omicron Period

    by Yun Lu, Kathryn Matuska, Rowan McEvoy, Hector S Izurieta, Jessica Rose Hervol, Mikhail Menis, Arnstein Lindaas, Whitney R Steele, Yoganand Chillarige, Michael Wernecke, et al.

    Background: We assessed the added benefit and waning effectiveness of a third COVID-19 vaccine dose (original formula) for preventing COVID-19–related outcomes. Methods: We used Medicare claims data to conduct a retrospective cohort study in US community-dwelling Medicare Fee-for-Service beneficiaries aged ≥65 years during the BA.1/BA.2 Omicron period (19 December 2021–26 March 2022). We estimated relative vaccine effectiveness (RVE) of 3 vs 2 doses of mRNA COVID-19 vaccines using marginal structural Cox regression models. Results: Among 8 129 355 eligible beneficiaries, 73.4% were 3 dose vaccinated by 26 March 2022. At 14 to 60 days since vaccination, a third dose provided significant added benefit against COVID-19–related hospitalization for Moderna (RVE, 77.0%; 95% CI, 75.7%–78.2%) and Pfizer-BioNTech (RVE, 72.3%; 95% CI, 70.6%–73.8%). Added benefit was lower at >120 days. For those with prior medically attended COVID-19 diagnoses, Pfizer-BioNTech provided an added benefit for 120 days, while Moderna provided some added benefit at >120 days. Added benefit for either vaccine was higher against death as compared with less severe outcomes, which still decreased at >120 days. Conclusions: A third-dose COVID-19 vaccine provided significant added benefit against COVID-19–related hospitalization and death, even for beneficiaries with prior medically attended COVID-19 diagnoses. This added benefit decreased after 4 months.


  • Open Access

    Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States

    by J. Bradley Layton, Patricia C. Lloyd, Lauren S. Peetluk, Yixin Jiao, Djeneba Audrey Djibo, Joann F. Gruber, Jie Deng, Christine Bui, An-Chi Lo, Rachel P. Ogilvie, et al.

    With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID 19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID 19 vaccines—BNT162b2, mRNA-1273, and JNJ-7836735—in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID 19 and hospital/emergency department (ED)-diagnosed COVID 19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID 19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID 19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically-diagnosed and up to 9 months for hospital/ED-diagnosed COVID 19. VE differed by brand and variant era. Additional real-world research is needed as new variants and recommendations for updated vaccines have evolved.

  • Comparing the Centers for Medicare and Medicaid Services (CMS) enrollment data death dates to the National Death Index (NDI)

    by Dinci Pennap, Richard S. Swain, Sandia Akhtar, Jiemin Liao, Yuqin Wei, Jiaqi Li, Michael Wernecke, Thomas E. MaCurdy, Jeffrey A. Kelman, Andrew D. Mosholder, et al.

    Purpose: In the United States, the National Death Index (NDI) is the most complete source of death information, while epidemiologic studies with mortality outcomes often rely on U.S. Medicare data for outcome ascertainment. The purpose of this study was to assess the agreement of death information between the Centers for Medicare & Medicaid Services (CMS) Medicare enrolment data and NDI.Methods: Using Medicare and NDI data from 1999 through 2016, we identified Medicare beneficiaries who were reported dead in the CMS Medicare enrolment database (EDB) and Common Medicare Environment (CME), linked these beneficiaries to the NDI using CMS Health Insurance Claim number, and compared death dates between the two data sources. To assess agreement between our data sources, we calculated kappa scores; where a kappa of 1 indicates perfect agreement and a kappa of 0 indicates agreement equivalent to chance. We also examined CMS to NDI linkage and death date matching for stability over time.Results: Of the 36 785 640, Medicare beneficiaries reported dead in CMS enrollment data from 1999 to 2016, 97.5% were linked to the NDI. A kappa score of 0.98 showed a near perfect agreement between NDI and CMS reported deaths. The percentage of linked cases exactly matching on death dates increased from 94.8% in 1999 to 99.4% in 2016.Conclusions: Our findings suggest strong concordance between death dates as recorded by CMS enrollment data and the NDI in the entire Medicare population.


  • Open Access

    Mortality risk after COVID-19 vaccination: A self-controlled case series study

    by Stanley Xu, Lina S. Sy, Vennis Hong, Paddy Farrington, Sungching C. Glenn, Denison S. Ryan, Abraelle M. Shirley, Bruno J. Lewin, Hung-Fu Tseng, Gabriela Vazquez-Benitez, et al.


  • Open Access

    Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States

    by J. Bradley Layton, Lauren Peetluk, Hui Lee Wong, Yixin Jiao, Djeneba Audrey Djibo, Christine Bui, Patricia C. Lloyd, Joann F. Gruber, Michael Miller, Rachel P. Ogilvie, et al.